Clinical relevance of drug interactions in people living with human immunodeficiency virus on antiretroviral therapy - Update 2022: systematic review

ABSTRACT: Background: The clinical outcomes of antiretroviral drugs may be modified through drug interactions; thus, it is important to update the drug interactions in people living with HIV (PLHIV). Aim: To update clinically relevant drug interactions in PLHIV on antiretroviral therapy with novel drug interactions published from 2017 to 2022. Methods: A systematic review in Medline/PubMed database from July 2017 to December 2022 using the Mesh terms antiretroviral agents and drug interactions or herb–drug interactions or food–drug interactions. Publications with drug interactions in humans, in English or Spanish, and with full-text access were retrieved. The clinical relevance of drug interactions was grouped into five levels according to the gravity and probability of occurrence. Results: A total of 366 articles were identified, with 219 (including 87 citation lists) were included, which allowed for the identification of 471 drug interaction pairs; among them, 291 were systematically reported for the first time. In total 42 (14.4%) and 137 (47.1%) were level one and two, respectively, and 233 (80.1%) pairs were explained with the pharmacokinetic mechanism. Among these 291 pairs, protease inhibitors (PIs) and ritonavir/cobicistat-boosted PIs, as well as integrase strand transfer inhibitors (InSTIs), with 70 (24.1%) and 65 (22.3%) drug interaction pairs of levels one and two, respectively, were more frequent. Conclusions: In PLHIV on antiretroviral therapy, we identify 291 drug interaction pairs systematically reported for the first time, with 179 (61.5%) being assessed as clinically relevant (levels one and two). The pharmacokinetic mechanism was the most frequently identified. PIs, ritonavir/cobicistat-boosted PIs, and InSTIs were the antiretroviral groups with the highest number of clinically relevant drug interaction pairs (levels one and two).

• Autores: Rivera Cadavid, Mónica Patricia; Amariles Muñoz, Pedro; Ceballos Rueda, Javier Mauricio
• Tipo de recurso: Review article
• Fecha de publicación: 2023
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/40656
• Acceso en línea: https://hdl.handle.net/10495/40656
• Palabra clave: Interacciones Farmacológicas; Drug Interactions; Antirretrovirales; Anti-Retroviral Agents; VIH; HIV; Síndrome de Inmunodeficiencia Adquirida; Acquired Immunodeficiency Syndrome; https://id.nlm.nih.gov/mesh/D004347; https://id.nlm.nih.gov/mesh/D044966; https://id.nlm.nih.gov/mesh/D006678; https://id.nlm.nih.gov/mesh/D000163
• Rights: openAccess
• License: http://creativecommons.org/licenses/by/2.5/co/